MUC1 and non-small cell lung carcinoma: A phase I trial of MUC1-targeted CAR-T cells with PD-1 knockout through CRISPR-Cas9 for the treatment of NSCLC patients (NCT03525782) had manageable toxicity and no grade 3–5 adverse events.